Market Research Publication: Irritable Bowel Syndrome Treatment Market 2022-2028
Growing prevalence of irritable bowel syndrome associated with lifestyle factors, stress, and increasing number of options for the treatment are expected to be the major factors driving the growth of the global irritable bowel syndrome treatment market over the forecast period. Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for symptom specific irritable bowel syndrome. Allergan plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS in adult men and women in 2015. Also, the company received approval of Health Canada for IBS-D in 2017. Get More Insights (at) https://www.coherentmarketinsights.com/market-insight/irritable-bowel-syndrome-treatment-market-506
Growing prevalence of irritable bowel syndrome associated with lifestyle factors, stress, and increasing number of options for the treatment are expected to be the major factors driving the growth of the global irritable bowel syndrome treatment market over the forecast period. Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for symptom specific irritable bowel syndrome. Allergan plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS in adult men and women in 2015. Also, the company received approval of Health Canada for IBS-D in 2017.
Get More Insights (at) https://www.coherentmarketinsights.com/market-insight/irritable-bowel-syndrome-treatment-market-506
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
GLOBAL<br />
IRRITABLE BOWEL<br />
SYNDROME TEATMENT<br />
MARKET<br />
<strong>Market</strong> Size (2019)<br />
US$ 1,044.9<br />
MN<br />
CAGR (2019 –<br />
2027)<br />
12.9%<br />
© Coherent <strong>Market</strong> Insights. All Rights Reserved
Segmentation (Scope)<br />
By Medical Condition<br />
By Drug Type<br />
By Distribution Channel<br />
<br />
IBS-constipation<br />
<br />
Lubiprostone<br />
<br />
Hospital Pharmacies<br />
<br />
IBS-diarrhea<br />
<br />
Linaclotide<br />
<br />
Online Pharmacies<br />
<br />
Eluxadoline<br />
<br />
Retail Pharmacies<br />
<br />
Rifaximin<br />
<br />
Alosetron<br />
<br />
Others<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Major Drivers<br />
<br />
Increasing launches and<br />
regulatory approvals<br />
<br />
Increase in the adoption of inorganic<br />
strategies by the manufacturers<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
NORTH<br />
AMERICA<br />
<strong>Market</strong> Size (2019)<br />
US$ 356.3 MN<br />
CAGR<br />
9.1%<br />
Major Drivers<br />
Major Drivers<br />
ASIA<br />
PACIFIC<br />
<strong>Market</strong> Size (2019)<br />
US$ 241.3 MN<br />
CAGR<br />
13.3%<br />
<br />
<br />
Increased prevalence of irritable bowel syndrome<br />
among the population<br />
Increase in research and development of new<br />
therapeutic products for treatment of IBS<br />
<br />
<br />
Increasing adoption of inorganic strategies by<br />
manufacturers to expand their presence in the region<br />
Increasing prevalence of irritable bowel syndrome<br />
among the population<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Major Players<br />
Abbott Laboratories<br />
Astellas Pharma Inc.<br />
Bausch Health Companies<br />
Novartis AG<br />
Mallinckrodt plc.<br />
GlaxoSmithKline plc.<br />
Ardelyx, Inc.<br />
Luoxin Pharmaceutical Group Co., Ltd.<br />
Alfasigma USA, Inc.<br />
Ironwood Pharmaceuticals Inc.<br />
© Coherent © Coherent <strong>Market</strong> <strong>Market</strong> Insights. All All Rights Rights Reserved Reserved
Change language